Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma
Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens.
A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast to the market. With the diversity in the pipeline, there is hope that innovative products can make it to market to provide patients with greater therapeutic options, while meeting unmet needs within ovarian cancer. There are 179 ovarian cancer pipeline products associated with a first-in-class molecular target representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. Such a diverse and innovative pipeline implies that approaches to ovarian cancer treatment are changing and first-in-class development is playing a significant role in this.
Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset.
What survival benefits do current therapies provide?
What are the current unmet needs that the pipeline needs to address?
The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
What potential do mAbs have in ovarian cancer treatment?
Will pipeline diversity translate to clinically and commercially successful therapies?
How are common target families, such as intracellular signal transduction associated with pathophysiology?
52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.
Do first-in-class products show strong progression into the later stages?
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=499491
Why is the greatest number of first-in-class products seen in signal transduction?
First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways
How well are first-in-class targets, such as Notch, aligned to known disease causing pathways?
Which targets are specifically found in early-stage development?
What is the industry-wide interest in these targets?
Co-development deals for first-in-class products are typically higher value than non-first-in-class counterparts.
To what extent does first-in-class status influence deal value and phase?
Can biologics command a greater deal value than other molecule types?
Reasons to buy
This report will allow you to
Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
Visualize the composition of the ovarian cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Analyze the ovarian cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating ovarian cancer.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=499491
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 State Street,
Albany NY - 12207
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma here
News-ID: 527943 • Views: 202
More Releases from Ovarian Cancer
Ovarian Cancer - US Market Insights, Epidemiology and Market Forecast-2020
ALBANY, NY, April 6, 2017 : DelveInsights Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer from 2012-2020. According to DelveInsight, the forecasted patient population of Ovarian cancer will decrease at a CAGR
Recent Study on Ovarian Cancer Identifying and Commercializing First-in-Class In …
Researchmoz added Most up-to-date research on "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is
Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017
Researchmoz added Most up-to-date research on "Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017" to its huge collection of research reports. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells
Global Historical And Forecasted Epidemiological Data For Diagnosed Incident Cas …
ResearchMoz presents this most up-to-date research on "Global Historical And Forecasted Epidemiological Data For Diagnosed Incident Cases Of Ovarian Cancer From 2017 - 2020". DelveInsights Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer
More Releases for Tel:
Semiconductor Assembly Equipment Market 2017 -TEL, DISCO, EVG, Shinkawa
Apex Research, recently published a detailed market research study focused on the "Semiconductor Assembly Equipment Market" across the global, regional and country level. The report provides 360° analysis of "Semiconductor Assembly Equipment Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Semiconductor Assembly Equipment industry, and estimates the future trend of Semiconductor
Tel Aviv University Announces Collaboration with Biosynth on Pioneering Chemilum …
STAAD, SWITZERLAND and TEL AVIV, ISRAEL, AUGUST 14, 2017 – Biosynth, a global company supplying intermediate chemicals to the life science industry and Tel Aviv University (TAU) through Ramot its Business Engagement Center, announce the signing of a licensing agreement giving Biosynth the right to manufacture and sell probes invented by Prof. Doron Shabat from the TAU School of Chemistry. Prof. Doron Shabat has developed a series of Dioxetane
OTS Attending Dealmakers Summit 2012 at Hilton Tel Aviv, Israel
Gurgaon, India - OTS Solutions (“OTS”) today announced that they will be attending Israel Dealmakers Summit 2012 at Hilton Tel Aviv, Israel from 20th February to 21st February, 2012. Gaurav Sethi, Manager Business Development of OTS Solutions, will be attending the event on behalf of the company and will be meeting the potential clients, prospects to grow the business and help the companies into their IT needs. We are hoping that
The Association for Tourism Tel Aviv – Jaffa Has Escalated the Connotation of …
Tel Aviv Israel, 17th December 2010 – Tel Aviv Travel and Tourism is gaining worldwide popularity thanks to the The Association for Tourism Tel Aviv – Jaffa which is essentially a foremost Municipal Company. It is owned by the Tel Aviv Jaffa Municipality. The principal aim of this body is to sustain and escalate this white city’s beautiful depiction with all round development and enhance domestic as well as foreign
Tel-Domains: Great Opportunities for "gold digger"
With less than some days until the start of the .tel Landrush, Telnic Limited, the registry operator for the new tel-domains, announced today that it will not be holding any auctions for high value or premium domain names nor is it withholding any tel-domains from the Landrush, with the exception of a few names on a "reserved list" as required by ICANN and as needed for registry operations. “People
TEL electronics, inc. Launches New Website
TEL electronics, inc. is proud to announce the launch of its new website, tel-electronics.com. Interested customers can now watch presentations, browse support manuals, view product brochures, screenshots, and specifications, and learn more about how call accounting can help their specific industry. Online presentations, such as “Cutting Telecom Costs”, explain how the WIN-SENSE 32 can help businesses lower expenses by decreasing phone abuse, eliminating toll fraud, optimizing phone system performance, and